323 related articles for article (PubMed ID: 33292107)
1. Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters.
Rendic S; Guengerich FP
Curr Drug Metab; 2020; 21(14):1127-1135. PubMed ID: 33292107
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
Rendic SP
Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
[TBL] [Abstract][Full Text] [Related]
3. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
Gelboin HV; Krausz KW; Shou M; Gonzalez FJ; Yang TJ
Pharmacogenetics; 1997 Dec; 7(6):469-77. PubMed ID: 9429232
[TBL] [Abstract][Full Text] [Related]
4. Renal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).
Knights KM; Rowland A; Miners JO
Br J Clin Pharmacol; 2013 Oct; 76(4):587-602. PubMed ID: 23362865
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes.
Kim KA; Park JY; Lee JS; Lim S
Arch Pharm Res; 2003 Aug; 26(8):631-7. PubMed ID: 12967198
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of potential herb-drug interactions based on the effect of Suxiao Jiuxin Pill on CYP450 enzymes and transporters.
Qiang T; Li Y; Wang K; Lin W; Niu Z; Wang D; Wang X
J Ethnopharmacol; 2021 Nov; 280():114408. PubMed ID: 34252529
[TBL] [Abstract][Full Text] [Related]
7. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor.
Reese MJ; Savina PM; Generaux GT; Tracey H; Humphreys JE; Kanaoka E; Webster LO; Harmon KA; Clarke JD; Polli JW
Drug Metab Dispos; 2013 Feb; 41(2):353-61. PubMed ID: 23132334
[TBL] [Abstract][Full Text] [Related]
8. Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.
Bleasby K; Houle R; Hafey M; Lin M; Guo J; Lu B; Sanchez RI; Fillgrove KL
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452431
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome-P450-Mediated Drug
Steyn SJ; Varma MVS
Mol Pharm; 2020 Aug; 17(8):3024-3032. PubMed ID: 32589434
[TBL] [Abstract][Full Text] [Related]
10. Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes.
Patten CJ; Smith TJ; Murphy SE; Wang MH; Lee J; Tynes RE; Koch P; Yang CS
Arch Biochem Biophys; 1996 Sep; 333(1):127-38. PubMed ID: 8806763
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.
Yang TJ; Sai Y; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1998 Oct; 8(5):375-82. PubMed ID: 9825829
[TBL] [Abstract][Full Text] [Related]
12. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes.
Guengerich FP; Wilkey CJ; Phan TTN
J Biol Chem; 2019 Jul; 294(28):10928-10941. PubMed ID: 31147443
[TBL] [Abstract][Full Text] [Related]
14. Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail.
Adedoyin A; Frye RF; Mauro K; Branch RA
Br J Clin Pharmacol; 1998 Sep; 46(3):215-9. PubMed ID: 9764961
[TBL] [Abstract][Full Text] [Related]
15. Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5.
Baune B; Flinois JP; Furlan V; Gimenez F; Taburet AM; Becquemont L; Farinotti R
J Pharm Pharmacol; 1999 Apr; 51(4):419-26. PubMed ID: 10385214
[TBL] [Abstract][Full Text] [Related]
16. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database.
Isoherranen N; Hachad H; Yeung CK; Levy RH
Chem Res Toxicol; 2009 Feb; 22(2):294-8. PubMed ID: 19216580
[TBL] [Abstract][Full Text] [Related]
17. Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method.
Yang X; Atkinson K; Di L
Drug Metab Dispos; 2016 Mar; 44(3):460-5. PubMed ID: 26700955
[TBL] [Abstract][Full Text] [Related]
18. Interactions of mammalian cytochrome P450, NADPH-cytochrome P450 reductase, and cytochrome b(5) enzymes.
Shimada T; Mernaugh RL; Guengerich FP
Arch Biochem Biophys; 2005 Mar; 435(1):207-16. PubMed ID: 15680923
[TBL] [Abstract][Full Text] [Related]
19. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
[TBL] [Abstract][Full Text] [Related]
20. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies.
Wang L; Zhang D; Raghavan N; Yao M; Ma L; Frost CE; Maxwell BD; Chen SY; He K; Goosen TC; Humphreys WG; Grossman SJ
Drug Metab Dispos; 2010 Mar; 38(3):448-58. PubMed ID: 19940026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
